Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE: NLS-2 (Mazindol ER) in Narcolepsy Type 1
NCT05914194Phase 3Not yet recruiting
- Sponsor
- NLS Pharmaceutics AG
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Mazindol ER in narcolepsy type 1 (NT1), sponsored by NLS Pharmaceutics AG. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Mazindol ER
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT05914194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05914194.